NSCLC患者-话题@MedSci

#NSCLC患者#

171篇内容 | 3005人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1410922, encodeId=0e37141092297, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, objectType=article, longId=295592, objectId=e4e3295592aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e3295592aa, replyNumber=0, likeNumber=87, createdTime=2022-02-15, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e3295592aa, moduleTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e3295592aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410921, encodeId=4bd31410921fa, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, objectType=article, longId=295315, objectId=4e7b295315f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7b295315f7, replyNumber=0, likeNumber=68, createdTime=2022-02-10, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7b295315f7, moduleTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7b295315f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410920, encodeId=4ae8141092060, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, objectType=article, longId=295314, objectId=762829531471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762829531471, replyNumber=0, likeNumber=62, createdTime=2022-02-10, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762829531471, moduleTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762829531471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410918, encodeId=5d0314109183f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=69, createdTime=2022-02-10, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410919, encodeId=90c214109192e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, objectType=article, longId=295258, objectId=d4ed295258b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ed295258b0, replyNumber=0, likeNumber=72, createdTime=2022-02-09, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ed295258b0, moduleTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ed295258b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410917, encodeId=afb6141091ec4, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=79, createdTime=2022-02-06, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410916, encodeId=1eda14109165c, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=71, createdTime=2022-02-05, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410915, encodeId=104a1410915e9, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, objectType=article, longId=294587, objectId=24a229458ebf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24a229458ebf, replyNumber=0, likeNumber=72, createdTime=2022-01-25, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24a229458ebf, moduleTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24a229458ebf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410914, encodeId=aaea1410914fc, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, objectType=article, longId=294238, objectId=ea07294238cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea07294238cf, replyNumber=0, likeNumber=70, createdTime=2022-01-20, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea07294238cf, moduleTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea07294238cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410913, encodeId=529c14109135d, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效, objectType=article, longId=294168, objectId=9ceb29416816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ceb29416816, replyNumber=0, likeNumber=65, createdTime=2022-01-20, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ceb29416816, moduleTitle=Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ceb29416816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410912, encodeId=527d1410912bb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=78, createdTime=2022-01-16, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410911, encodeId=7fc114109117f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, objectType=article, longId=293790, objectId=a320293e9099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a320293e9099, replyNumber=0, likeNumber=69, createdTime=2022-01-12, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a320293e9099, moduleTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a320293e9099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410910, encodeId=d4bf14109100a, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, objectType=article, longId=293621, objectId=07a32936217f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07a32936217f, replyNumber=0, likeNumber=98, createdTime=2022-01-10, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07a32936217f, moduleTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07a32936217f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410909, encodeId=ed4a14109096b, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=58, createdTime=2021-12-23, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410908, encodeId=d5c414109089a, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=42, createdTime=2021-12-21, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410907, encodeId=31d3141090e7b, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=65, createdTime=2021-12-16, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410906, encodeId=762e141090605, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, objectType=article, longId=264988, objectId=11502649888a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11502649888a, replyNumber=0, likeNumber=127, createdTime=2021-12-13, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11502649888a, moduleTitle=Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11502649888a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410905, encodeId=4bab1410905fd, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, objectType=article, longId=221572, objectId=bfd12215e24f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd12215e24f, replyNumber=0, likeNumber=57, createdTime=2021-12-07, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd12215e24f, moduleTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfd12215e24f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410904, encodeId=ec651410904d0, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, objectType=article, longId=221412, objectId=45d222141221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d222141221, replyNumber=0, likeNumber=71, createdTime=2021-12-03, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d222141221, moduleTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d222141221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410903, encodeId=7e79141090332, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=69, createdTime=2021-12-01, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NSCLC患者

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后

2022-02-15

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效

2022-02-10

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系

2022-02-10

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-02-10

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响

2022-02-09

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-02-06

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-02-05

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后

2022-01-25

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效

2022-01-20

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效

2022-01-20

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控

2022-01-16

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后

2022-01-12

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素

2022-01-10

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2021-12-23

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2021-12-21

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2021-12-16

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：伴有罕见突变的晚期或转移性NSCLC患者的真实世界数据

2021-12-13

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效

2021-12-07

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性

2021-12-03

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2021-12-01

科室
- - 订阅+
  - 更多科室
工具
服务